Retatrutide Phase 3 results are in. Eli Lilly announced positive topline data from TRIUMPH-1 today (May 21, 2026), the first registrational Phase 3 obesity trial for retatrutide. Participants on the 12 mg dose lost an average of 28.3% of their body weight at 80 weeks (efficacy estimand; 25.0% counting everyone randomized). Full results were later published in the New England Journal of Medicine on September 29, 2026. Those with a starting BMI of 35 or higher who continued on the drug lost up to 30.3% (an average 85.0 lbs) at 104 weeks. The dose-escalation 4 mg arm hit 19.0% weight loss with a discontinuation rate lower than placebo. Here's what the data shows and what it means for the FDA approval timeline.
🔑 Key Takeaways
- All three doses met primary and key secondary endpoints. 4 mg, 9 mg, and 12 mg vs placebo across an 80-week primary period.
- 12 mg dose: 28.3% body-weight loss (70.3 lbs from a 248.5 lb baseline; efficacy estimand). 62.5% of participants achieved at least 25% loss; 45.3% achieved at least 30%; 27.2% achieved at least 35%.
- 104-week extension was even stronger. Participants with baseline BMI of 35 or higher who stayed on the highest tolerated dose lost 30.3% (85.0 lbs) at two years. Weight loss continued past the 80-week mark rather than plateauing.
- 4 mg dose is a real option. 19.0% weight loss with just one escalation step and a discontinuation rate (4.1%) lower than placebo (4.9%). Useful for patients who don't tolerate higher doses.
- 65.3% of participants on 12 mg dropped below BMI 30 at 80 weeks, falling out of the obesity classification. 37.5% of those who started with class 3 obesity (BMI of 40 or higher) also crossed below 30.
- Safety: GI side effects dominate, as expected. Nausea 42.4% at 12 mg, vomiting 25.3%, diarrhea 32.0%. Dysesthesia (skin tingling) 12.5% at 12 mg. Discontinuation due to adverse events: 11.3% at 12 mg.
- Cardiometabolic improvements: Significant reductions in waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein (hsCRP).
Today's release is the biggest single Phase 3 obesity readout for retatrutide so far. Combined with the December 2025 TRIUMPH-4 trial (knee osteoarthritis + obesity), Lilly now has two successful Phase 3 readouts in the books. Since then, TRIUMPH-2 (obesity + type 2 diabetes) and TRIUMPH-3 (obesity + established cardiovascular disease) reported on July 23, 2026, and the full TRIUMPH-1 paper appeared in the New England Journal of Medicine on September 29, 2026.
Retatrutide Phase 3 Results: What TRIUMPH-1 Measured
TRIUMPH-1 enrolled 2,339 adults with obesity or overweight who had at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, or osteoarthritis) but no diabetes. The trial randomized them 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg, or placebo, all delivered as a once-weekly subcutaneous injection. The primary endpoint was percent change in body weight at 80 weeks.
Baseline characteristics: average weight 248.5 lbs, average BMI 40.0 kg/m². Dose escalation was step-wise every four weeks, starting at 2 mg and climbing in increments to the target dose. A pre-specified extension carried 532 participants (those with baseline BMI of 35 or higher who tolerated their assigned dose) out to 104 weeks total, with a blinded escalation to maximum tolerated dose.
The Headline Numbers
At the primary 80-week endpoint (efficacy estimand, i.e. people who stayed on treatment; counting everyone randomized, the figures were 17.6%, 23.7% and 25.0% vs 3.9% on placebo):
At the 104-week extension endpoint (baseline weight 268.3 lbs, BMI 42.8):
The single most quoted number from today's release will be the 30.3% figure at 104 weeks. That puts retatrutide in territory previously associated only with bariatric surgery (which produces 25 to 35% weight loss depending on procedure type, per the JAMA Surg 2014 NIH symposium Lilly cited in the press release).
Safety and Side Effects: What Stood Out
The safety profile is consistent with prior retatrutide trials and the broader GLP-1 class. GI symptoms dominated, scaled with dose:
Three things worth flagging:
- 4 mg discontinuation rate is below placebo. 4.1% vs 4.9%. That's unusual and points to the dose escalation schedule being the dominant driver of dropouts, not the drug itself. The 4 mg arm reaches it in one step from 2 mg.
- Dysesthesia at 9 and 12 mg was lower than what TRIUMPH-4 reported. TRIUMPH-1 showed 12.5% at 12 mg vs the 20.9% TRIUMPH-4 figure. Lilly notes it was generally mild to moderate and most participants stayed on treatment.
- UTI incidence was modestly elevated (7.5 to 8.8% on retatrutide vs 5.3% on placebo). Not in the FDA black box class, but worth flagging for clinicians.
For a deeper frequency-by-dose breakdown of every retatrutide side effect including management strategies, see our retatrutide side effects guide.
Retatrutide Phase 3 Results vs TRIUMPH-4, Tirzepatide and Semaglutide
TRIUMPH-1 is the obesity-only readout. TRIUMPH-4 (released December 11, 2025) studied obesity plus knee osteoarthritis and hit 28.7% weight loss at 12 mg over 68 weeks. The two are now the headline data anchors for retatrutide's regulatory package.
Retatrutide's TRIUMPH-1 12 mg result is among the largest average weight losses reported in a Phase 3 obesity trial (efficacy estimand; the smaller TRIUMPH-4 knee-osteoarthritis trial reported 28.7% at 12 mg on the same estimand), beating tirzepatide's SURMOUNT-1 by roughly 5.8 percentage points and semaglutide's STEP-1 by 13.4. The 30.3% figure at the 104-week extension is bigger than anything seen outside bariatric surgery. For a fuller side-by-side, see our retatrutide vs tirzepatide comparison.
What This Means for the FDA Approval Timeline
Successful Phase 3 readouts (TRIUMPH-4, TRIUMPH-1, then TRIUMPH-2 and TRIUMPH-3) put Lilly in position to file for retatrutide. The timeline as of October 2026:
- July 23, 2026: TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease) reported, and Lilly said its clinical package is complete.
- Q1 2027: Lilly's planned Biologics License Application submission — later than first indicated, because the manufacturing (CMC) package needed more time.
- Late 2027 at the earliest, more likely 2028: Realistic FDA decision window (about a year after submission on standard review; priority review could shorten it).
- 2028: Realistic commercial launch window if approved on standard review.
For the most current FDA approval tracker on retatrutide see our retatrutide FDA approval timeline page.
What's Coming Next in the TRIUMPH Program
TRIUMPH-1 is part of an eight-trial Phase 3 program with over 5,800 enrolled participants. The other parts of the program:
- TRIUMPH-2: Obesity or overweight plus type 2 diabetes. Reported July 23, 2026; full results in The Lancet on September 29, 2026 (20.8% at 12 mg, efficacy estimand).
- TRIUMPH-3: Severe obesity with established cardiovascular disease. Reported July 23, 2026: 22.6% weight loss at 12 mg, but the heart-event analysis was inconclusive (too few events), so it can't support a heart-protection label like semaglutide's SELECT result.
- TRIUMPH-OSA basket arms: Moderate-to-severe obstructive sleep apnea data (part of the TRIUMPH-1 basket structure).
- TRIUMPH-KOA basket arms: Additional knee-osteoarthritis data beyond TRIUMPH-4.
- Maintenance-dose strategies: Trials evaluating whether dose can be reduced after weight-loss targets are hit.
TRIUMPH-3's heart-event data turned out inconclusive, so whether retatrutide can be prescribed for cardiovascular prevention — which would dramatically expand the addressable patient pool and likely accelerate payer coverage — now depends on longer outcome studies.
How to Access Retatrutide Now
Retatrutide is investigational and not FDA approved. The four paths to access it in mid-2026:
- Clinical trial enrollment. TRIUMPH-2 and TRIUMPH-3 have finished, and no TRIUMPH trial is recruiting. As of October 2026 the only retatrutide study taking new volunteers is SYNERGY-Outcomes (liver disease); see our retatrutide clinical trials tracker.
- Compounding pharmacy via telehealth. Not a legal option. The FDA says retatrutide cannot be used in compounding under federal law and has warned telehealth firms and outsourcing facilities, and Lilly has sued a compounding pharmacy among other sellers.
- Peptide vendors. Sold without a prescription, most often as R-10 (10 mg) and R-30 (30 mg) vials. There is no medical oversight, so quality comes down to the seller's third-party testing: if you buy retatrutide this way, check the batch COA first.
- Wait for FDA approval. Late 2027 at the earliest, more likely 2028. Until then, Lilly runs a free, physician-led early access program for a narrow group of patients with severe obesity.
For the four-route breakdown with current pricing see how to get retatrutide in 2026 and where to buy retatrutide.
Frequently Asked Questions
📚 References
- Eli Lilly. "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial." Press release, May 21, 2026. Lilly investor page
- Eli Lilly. "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial." TRIUMPH-4 press release, December 11, 2025.
- TRIUMPH-1 clinical trial protocol: NCT05929066. ClinicalTrials.gov.
- Jastreboff AM et al. "Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial." N Engl J Med. 2023;389(6):514-526. PubMed
- Courcoulas AP, Yanovski SZ, Bonds D, et al. "Long-term outcomes of bariatric surgery: a National Institutes of Health symposium." JAMA Surg. 2014;149(12):1323-1329.






